FDA grants emergency use authorization for InflaRx's Gohibic (vilobelimab) for COVID-19 treatment.
The FDA has granted emergency use authorization for Gohibic (vilobelimab) injection for the treatment of COVID-19 in hospitalized adults who have received invasive mechanical ventilation or extracorporeal membrane oxygenation. The treatment targets a part of the immune system that is thought to play a role in the inflammation that leads to COVID-19 disease progression. Clinical trials showed that patients treated with Gohibic had a lower risk of death by day 28 and day 60 of treatment compared to placebo.